| |  | | | | By Mario Aguilar Alex Hogan/STAT, ADOBE For digital therapeutics companies, achieving widespread adoption isn't as simple as proving your products work. Read More | | By Kate Sheridan Hyacinth Empinado/STAT STAT looks at 3 forces that shaped the financial landscape for biotech companies in 2021 — and why they will drive the markets in 2022. Read More | | By Lev Facher Hyacinth Empinado/STAT STAT looked at Biden's Covid strategy and whether 2022 could finally be the year the pandemic fades into the background. Read More | | Sponsor content by STAT+ Biopharma breakthroughs, business, and policy analysis — at your fingertips Enjoy daily, market-moving analysis of the biotech, pharma, and life sciences industries with STAT Plus. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Don't be the last to know. Subscribe today to start reading. | | By David Introcaso ADOBE Given the well-documented correlation between income and health, HHS's lack of response to deaths of despair is beyond understanding. Read More | |
No comments